ID   CB-F7
AC   CVCL_9V08
SY   CBF-7; CBF7
DR   Wikidata; Q54808639
RX   PubMed=2828478;
RX   PubMed=7492749;
RX   PubMed=9708833;
CC   Group: Hybridoma fusion partner cell line.
CC   Selected for resistance to: ChEBI; CHEBI:472805; Ouabain.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybrid cell line
DT   Created: 23-02-16; Last updated: 21-03-23; Version: 6
//
RX   PubMed=2828478; DOI=10.1016/0022-1759(88)90206-2;
RA   Grunow R., Jahn S., Porstmann T., Kiessig S.S., Steinkellner H.,
RA   Steindl F., Mattanovich D., Gurtler L., Deinhardt F.W., Katinger H.,
RA   von Baehr R.;
RT   "The high efficiency, human B cell immortalizing heteromyeloma CB-F7.
RT   Production of human monoclonal antibodies to human immunodeficiency
RT   virus.";
RL   J. Immunol. Methods 106:257-265(1988).
//
RX   PubMed=7492749; DOI=10.3233/HAB-1995-6201;
RA   Delvig A.A., Koumare B., Glaser R.W., Wang J.-F., Jahn S., Achtman M.;
RT   "Comparison of three human-murine heteromyeloma cell lines for
RT   formation of human hybridomas after electrofusion with human
RT   peripheral blood lymphocytes from meningococcal cases and carriers.";
RL   Hum. Antibodies Hybridomas 6:42-46(1995).
//
RX   PubMed=9708833; DOI=10.1089/hyb.1998.17.299;
RA   Niedbala W.G., Stott D.I.;
RT   "A comparison of three methods for production of human hybridomas
RT   secreting autoantibodies.";
RL   Hybridoma 17:299-304(1998).
//